NOSTRUM PHARMACEUTICALS OBTAINS WORLDWIDE LICENSING RIGHTS FROM IMTECH FOR CLINICAL DEVELOPMENT OF A NOVEL CLOT BUSTING THERAPEUTIC PROTEIN

Pharmaceuticals Inc., a privately held company based in Kendall Park, New Jersey, announced that it has obtained a worldwide license from Institute of Microbial Technology (IMTECH), Chandigarh, India, to carry out clinical development and commercialization of a novel clot busting therapeutic protein.
BioSpace